8
Participants
Start Date
October 20, 2009
Primary Completion Date
November 28, 2009
Study Completion Date
November 28, 2009
GSK2248761
GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
Lopinavir/ritonavir
Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
HAART
Highly Active Antiretroviral therapy of the doctor's choice.
Placebo
Placebo is a capsule with no drug in it.
GSK2248761
GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
GSK Investigational Site, Buenos Aires
Lead Sponsor
Collaborators (1)
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY